Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Actelion joins chase of Flolan

Two separate Phase III successes in pulmonary hypertension could put pressure on Glaxo Wellcome's Flolan epoprostenol prostacyclin, the only marketed drug for the disorder. Actelion Ltd. last week released significant Phase III data on bosentan, following on

Read the full 377 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers